+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.

Age: 18Years +All GendersPhase 2
123 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 in people living with chronic kidney disease, some of whom have type 2 diabetes and are overweight or obese. This Phase 2 study also compares NNC0519-0130 to semaglutide, an already prescribed medicine, and a placebo to see how they may improve kidney function. Participants will be randomly assigned to receive once-weekly subcutaneous injections of NNC0519-0130 with a fixed dose escalation until reaching a maintenance dose, semaglutide with a similar dosing schedule, or a placebo matching NNC0519-0130. The treatment period lasts up to 43 weeks with several dosing schemes and groups. During the study, participants will have their kidney function monitored through urine albumin-to-creatinine ratio changes at weeks 12, 24, and 36. Other assessments include estimated glomerular filtration rate, body weight changes, waist circumference, blood pressure, and glycated hemoglobin levels. Safety will be evaluated by tracking adverse events throughout the trial duration. Participants will be regularly assessed to understand the medicines effects and safety.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.

Age: 65Years +All Genders
54 locations
P

Actively Recruiting

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.

Age: 18Years +All GendersPhase 3
265 locations
E

Actively Recruiting

Researchers are evaluating the effects of regular caffeine consumption versus caffeine abstinence on heart rate control in adults with permanent atrial fibrillation AF. The CAFIB trial is a multicenter, randomized, open-label crossover study designed to understand if moderate habitual caffeine intake affects heart rate management in this population, considering that traditional advice often recommends avoiding caffeine despite growing evidence suggesting moderate coffee consumption may not worsen AF and might offer cardiovascular benefits. Participants will be randomly assigned to one of two groups continuing their usual caffeinated coffee intake at least one cup daily or complete caffeine abstinence while allowing decaffeinated coffee. Energy drinks are prohibited for both groups. The study has no washout period between crossover phases due to caffeines short biological half-life. Adherence to caffeine intake or abstinence will be monitored through diaries and interviews during the study. Participants will attend three scheduled visits over 60 days at baseline, 30 days, and 60 days. Each visit includes clinical assessments, ECG, 24-hour Holter monitoring to measure heart rate, blood sampling, and quality-of-life questionnaires. The primary outcome is the 24-hour mean heart rate. Secondary outcomes include changes in heart rate, symptom severity, quality of life, heart failure biomarkers, adverse events, and medication changes. The study aims to recruit 50 patients and includes careful statistical analysis to assess the impact of caffeine on heart rate control.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
1 location
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
S

Actively Recruiting

Researchers are evaluating the effect of continued nutritional support after hospital discharge compared to usual care in medical patients at nutritional risk. This trial focuses on adults who have experienced malnutrition, a condition linked to higher risks of death, rehospitalization, and loss of function, especially among elderly and multi-ill patients. Previous studies showed that in-hospital nutritional support helps reduce complications and mortality, but the long-term benefits after discharge remain unclear. Participants are randomly assigned to one of two groups. The intervention group receives customized nutritional support from an experienced dietician to meet their individual energy and protein needs, including oral nutritional supplements as needed. The control group receives general advice on healthy eating habits at discharge without ongoing nutritional support. Follow-up includes regular phone calls every 2 to 4 weeks to monitor adherence and adjust dietary plans as necessary. During the study, participants are monitored for up to three years. Researchers assess key outcomes such as time to death from any cause, hospital readmissions, major complications, and changes in functional status using the Barthel index. Quality of life is measured with the European Quality of Life 5 Dimensions index and a visual-analogue scale at regular intervals by phone. This comprehensive follow-up helps determine whether sustained nutritional support after discharge improves long-term health and recovery.

Age: 18Years +All GendersPhase Not Applicable
18 locations
S

Actively Recruiting

Researchers are evaluating the use of angiogenic markers sFlt-1PlGF ratio to manage delivery timing in women with preeclampsia without severe features between 36 and 386 weeks of pregnancy. The study aims to see if basing delivery decisions on these markers can reduce the need for labor induction without increasing the risk of developing severe preeclampsia or other maternal complications. This is an open-label, randomized controlled trial sponsored by Hospital Universitari Vall dHebron Research Institute. Participants are randomly assigned to one of two groups. In the intervention group, if angiogenic markers are normal sFlt-1PlGF <38, delivery is delayed until 39 weeks if abnormal sFlt-1PlGF 38, labor induction is recommended at or after 37 weeks. The control group receives the current standard care with elective delivery scheduled at 37 weeks. Both groups have NT-proBNP levels measured at enrollment, and delivery is immediately recommended if any urgent maternal or fetal conditions arise. During the study, participants complete satisfaction questionnaires at enrollment and four weeks postpartum. Researchers monitor maternal and neonatal outcomes, including complications, ICU admissions, gestational age at delivery, birthweight, and maternal NT-proBNP levels. The primary outcome is a composite of maternal health measures assessed through about two months after delivery. The study is expected to last until April 2028.

Age: 18Years +FEMALEPhase Not Applicable
23 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Age: 18Years +All Genders
84 locations
G

Actively Recruiting

Researchers are conducting an observational, multicenter, international study to learn about antimicrobial resistance AMR in people with chronic lung diseases CLD worldwide. The study aims to understand how common AMR is in these patients, how it varies by location, and what risk factors contribute to it. This study is non-pharmacological and collects data without adding any new treatments or procedures beyond usual care. Data will be collected at multiple centers during two separate two-week periods each year for five years. Participants include patients of all ages with chronic lung diseases who have had at least one respiratory sample collected within the past year. Clinical, demographic, and microbiological information will be gathered through questionnaires and medical records, all recorded in a secure electronic system. No additional tests or interventions outside routine clinical practice will be performed. Participants will provide informed consent before joining. Throughout the study, researchers will monitor the prevalence of antimicrobial resistance and analyze susceptibility patterns of key resistant pathogens, geographical differences, and risk factors for AMR by reviewing collected clinical and microbiological data. The study will last five years, with data collected periodically and securely maintained to better understand AMRs impact on chronic lung diseases.

All AgesAll Genders
68 locations

1-10 of 13

1